Huyabio concludes Phase I atrial fibrillation trial
The US Food and Drug Administration approved dose escalation in the Phase II HBI-3000-402 trial.
Cardiovascular
Latest in
Cardiovascular
Pipeline Moves: Pfizer terminates Phase II Braftovi, Mektovi trial, likely progress downturn in brain tumours
The Clinical Trials Arena team also review assets in postoperative pain, cardiogenic shock, and lymphoma.
By
Covid-19 diagnoses may drive increase in heart failure cases
As the Covid-19 pandemic stretches into its third year, the long-term effects of acute infection are beginning to become more…
By
Reduced risk of CV morbidity and mortality demonstrated in FIDELITY study
Data from the FIDELITY study will support the use of finerenone to improve cardiorenal outcomes for CKD and T2D patients.
By
BridgeBio Pharma presents long-term data from Phase II study of acoramidis
Acoramidis will vie for a share of the transthyretin amyloidosis cardiomyopathy population, which Vyndaqel currently dominates.
By
BMS’ mavacamten boosts cardiovascular outcomes in obstructive HCM study
The safety profile of the oral therapy in the EXPLORER-LTE cohort was in line with the EXPLORER-HCM trial.
KalVista commences Phase III trial of oral hereditary angioedema treatment
The company plans to report results from the clinical trial of KVD900 in the second half of next year.
Intellia, Regeneron report positive Phase I transthyretin amyloidosis data
Findings showed that NTLA-2001 provided a dose-dependent decline in serum TTR and attained maximal reductions by day 28.